

Supplementary Table 9. Type of post-acute COVID-19 symptoms.

| Study, year | Type of symptoms |
|-------------------|--|
| Caffero, 2021 | No case of long COVID was found. |
| Erickson, 2021 | 16 (9.4%) athletes had symptoms at the time of examination. Mean \pm SD time between positive test result and medical screening: 22.5 \pm 14.2 |
| Gervasi, 2021 | All athletes were asymptomatic for COVID-19-related symptoms at the time of screening. |
| Hendrickson, 2021 | No athlete had new symptoms or any problems after resuming exercise or during competition. |
| Hull, 2021 | 21 (14%) athletes had symptoms > 28 days and 5 (3%) had symptoms lasting > 90 days. Fatigue (71%), cough (57%), headache (52%), fever (43%), dyspnea (38%), sore throat (29%), anosmia/dysgeusia (24%), myalgia (19%), chest pain (10%), diarrhea (5%), nausea (5%), dizziness (5%), abdominal pain (5%) |
| Hwang, 2021 | All student-athletes have returned to exercise and athletic activity without complication. |
| Komici, 2021 | 19 (79%) had persistent symptoms. Anosmia/dysgeusia (46%), rhinitis (21%), cough (17%), and myalgia (8%) |
| Krzywański, 2022 | 20 (18%) athletes reported abnormal symptom at the medical screening. Median (range) time between COVID-19 diagnosis and medical screening: 20 (12 – 68) days Anosmia/dysgeusia (6%), feeling of decreased exercise tolerance (3%), headache (1%) |
| Milovancev, 2021 | Participants had no residual symptoms of COVID-19 in the moment of testing. |
| Petek, 2021 | 44 (1.2%) athletes had persistent symptoms > 3 weeks from symptom onset; 137 (4%) athletes had exertional cardiopulmonary symptoms on return to exercise. Persistent symptoms: Anosmia/dysgeusia (63%), shortness of breath (20%), cough (15%), chest pain (15%), fatigue (10%), headache (5%), loss of appetite (3%), nasal congestion (3%), rhinorrhea (3%), light-headedness (3%). Exertional symptoms on return to exercise: short of breath (58%), chest pain (36%), exercise intolerance (23%), palpitations (7%), pre-syncope/syncope (4%). |
| Shah, 2021 | None of the athletes reported persistent or recurrent symptoms, limitations, or adverse events following resumption of training. |